Evaluate

Fill in the gaps on Pharma

Providing data and insight for the professionally curious.

At Evaluate, we provide news, analysis, data and insight for the professionally curious. We don’t tell you what to think. Instead, we believe it’s more important that you can ask your own questions and have the information to draw your own conclusions. So you can fill in the gaps on pharma - and spot opportunities others miss.

Vantage Daily

Free pharmaceutical news and analysis to stimulate your thoughts.

EvaluatePharma Vision

The commercial data to build your response.

Evaluate provides everything you need to build an informed view on pharma

  • Add context to market-leading consensus forecasts to 2024 with combined proprietary R&D analytics, including success rates and predictive timelines.
  • Understand the true risk of an R&D investment with clinical trial and product-level costs and outcomes.
  • Get a forward-looking view with a calendar of market events and catalysts that may affect company and product value.
  • Independent, data-driven daily news and analysis on pharma, biotech and medtech to kick-start your thinking.


"EvaluatePharma Vision is one of the most robust offerings for commercial sales data, probability of success and time-in-phase data in a single platform.

We recently completed an R&D forecasting project and couldn't have done the work without it."


Matthew C., Director, R&D Strategy and Operations, Gilead

Discover data and analysis to fill in the gaps in pharma

All done!

All done!

Check your inbox for an email from Vantage to confirm your subscription.
We will be in touch shortly to arrange your EvaluatePharma Vision demo.
Download your white paper, “The Importance of Curiosity”, here.
Download your white paper, “Risk and Return in Pharma”, here.
Thanks for your interest in Evaluate

Thanks for your interest in Evaluate

Three resources for the professionally curious

Schedule EvaluatePharma Vision demo >
Stimulus      
Daily news with expert analysis
Interviews with industry leaders
Company & product events coverage
Response      
Consensus forecasts to 2024  
Archived consensus forecasts  
Sales by indication  
Therapy area, mechanism of action, and other classifications  
Licensing deals, M&A, venture financing and IPOs  
Orphan drugs and biosimilars analysis  
Success rate benchmarks (PTRS)    
Time-in-phase benchmarks by indication    
Comprehensive product and trial level R&D costs    
Clinical trials design and outcomes    
Net Present Value calculator    
Calendar of market events and catalysts    

Free pharmaceutical news and analysis to provoke questions

Vantage Daily
  • Understand breaking news with data-driven analysis.
  • Identify key industry events with a forward-looking overview.
  • Stay informed of the latest regulatory and patent decisions, and M&A.
  • Read exclusive interviews with industry leaders.
SIGN UP NOW >

The commercial data to fill in the gaps and spot the opportunities others miss

EvaluatePharma Vision
  • Market-leading consensus forecasts to 2024.
  • Proprietary R&D analytics including success rates and predictive timelines.
  • Clinical trial design and outcomes.
  • Calendar of market events.
  • Net Present Value calculator.
SCHEDULE A DEMO >

Here's what our clients are saying:

PHARMA

We know Evaluate has done the work and looked at the data, and we trust the answers they give us. Our management is happy when they see Evaluate’s names on the data.

- Anthony M, Senior Director Competitive Intelligence & Prospection, Novartis

"Evaluate is a source you don't have to justify… Everybody is in agreement about the accuracy. Not only does this mean we don’t need to do all the work ourselves, but it also saves time because we don't have to debate the numbers. Our management is happy when they see Evaluate's name on the data."


CONSULTANCY

Evaluate accelerates my work - getting me up to speed quickly on the dynamics and current valuations within a market so I can formulate a successful strategy for my client.

- Partner, Top 10 Consultancy

"We usually have a limited amount of time to create the best, most robust solution for a client. Evaluate makes it easy to pivot from a company’s portfolio and pipeline to the key therapy areas they compete in, and get a complete view of R&D pipelines, sales expectations, patent expiries, mechanisms and more. Spending less time on the upfront research lets me focus on developing insights that add value, so I can have more meaningful, direct conversations with my clients about the opportunities and risks for their business."


BANKING

Evaluate is such an important resource for us. Finding the information we need in ten minutes in Evaluate makes a meaningful difference for our clients, because we can increase the quantity and quality of options we show them.

- Vishwas S, Vice President, Bank of America

"We're pushing to incorporate Evaluate more in our workstreams, especially with the new functionality that has been added over time. I can't imagine doing our job without it, and it should be part of the package for anyone working in life sciences investment banking."


FAQs

What does Evaluate do?

We collect, calibrate and connect pharmaceutical world’s information to help our clients make the best strategic decisions. Evaluate's beginning focused on providing consensus forecasts that distilled the insight of pharmaceutical equity analysts around the world. These remain the foundation of our solutions.


What is the relationship between Evaluate and Vantage?

Vantage is an independent editorial arm of Evaluate. Vantage’s unique access to Evaluate's data provides fresh angles and insight on both current and future industry triggers.


What is EvaluatePharma Vision?

EvaluatePharma Vision combines our unparalleled consensus forecasts with breakthrough insights on the risk and return of the R&D landscape. Our clients include all the top 20 global pharma companies, growing biotechs, investment banks, management consultancies, and leading pharmaceutical service providers.


What do I get if I sign up to Vantage Daily?

You’ll receive a daily email with all the latest industry news coupled with high-quality analysis from our award-winning journalist team.